Evidence map›Paper›PMID 36313971›Full record

ReviewBiotechnology and bioprocess engineering : BBE2022

Influenza Vaccine: An Engineering Vision from Virological Importance to Production.

S Furkan Demirden, Kadir Alptekin, Ilgin Kimiz-Gebologlu, Suphi S Oncel

Abstract readReview
In one paragraph

Review in Biotechnology and bioprocess engineering : BBE, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

S Furkan DemirdenDepartment of Bioengineering, Faculty of Engineering, Ege University, Izmir, 35100 Turkey.
Kadir AlptekinDepartment of Bioengineering, Faculty of Engineering, Ege University, Izmir, 35100 Turkey.
Ilgin Kimiz-GebologluDepartment of Bioengineering, Faculty of Engineering, Ege University, Izmir, 35100 Turkey.
Suphi S OncelDepartment of Bioengineering, Faculty of Engineering, Ege University, Izmir, 35100 Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to data from the World Health Organization (WHO) every year, millions of people are affected by flu. Flu is a disease caused by influenza viruses. For preventing this, seasonal influenza vaccinations are widely considered the most efficient way to protect against the negative effects of the flu. To date, there is no "one-size-fits-all" vaccine that can be effective all over the world to protect against all seasonal or pandemic influenza virus types. Because influenza virus transforms its genetic structure and it can emerges as immunogenically new (antigenic drift) which causes epidemics or new virus subtype (antigenic shift) which causes pandemics. As a result, annual revaccination or new subtype viral vaccine development is required. Currently, three types of vaccines (inactivated, live attenuated, and recombinant) are approved in different countries. These can be named "conventional influenza vaccines" and their production are based on eggs or cell culture. Although, there is good effort to develop new influenza vaccines for broader and longer period of time protection. In this sense these candidate vaccines are called "universal influenza vaccines". In this article, after we mentioned the short history of flu then virus morphology and infection, we explained the diseases caused by the influenza virus in humans. Afterward, we explained in detail the production methods of available influenza vaccines, types of bioreactors used in cell culture based production, conventional and new vaccine types, and development strategies for better vaccines.

Indexed as

cell culture-based vaccine productioninfluenza vaccineinfluenza vaccine development strategiesinfluenza virusvaccine manufacturingvaccine production in bioreactors

Identifiers

PMID36313971
PMCPMC9589582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.